Vhl deficiency in osteocytes produces high bone mass and hematopoietic defects.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30172741.
- Also identified by DOI 10.1016/j.bone.2018.08.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tissue oxygen (O<sub>2</sub>) levels vary during development and disease; adaptations to decreased O<sub>2</sub> (hypoxia) are mediated by hypoxia-inducible factor (HIF) transcription factors. HIFs are active in the skeleton, and stabilizing HIF-α isoforms cause high bone mass (HBM) phenotypes. A fundamental limitation of previous studies examining the obligate role for HIF-α isoforms in the skeleton involves the persistence of gene deletion as osteolineage cells differentiate into osteocytes. Because osteocytes orchestrate skeletal development and homeostasis, we evaluated the influence of Vhl or Hif1a disruption in osteocytes. Osteocytic Vhl deletion caused HBM phenotype, but Hif1a was dispensable in osteocytes. Vhl cKO mice revealed enhanced canonical Wnt signaling. B cell development was reduced while myelopoiesis increased in osteocytic Vhl cKO, revealing a novel influence of Vhl/HIF-α function in osteocytes on maintenance of bone microarchitecture via canonical Wnt signaling and effects on hematopoiesis.
Medical subject headings
- Bone and Bones
- Hematopoiesis
- Osteocytes
- Von Hippel-Lindau Tumor Suppressor Protein